DMP 696 is a selective antagonist of corticotropin-releasing hormone receptor 1. It is used for the treatment of anxiety and depression.

DMP696 treatment decreases levels of LA and BLA pCREB across all time intervals that do not differ obviously from homecage pCREB levels. DMP696 (3?mg/kg, p.o.) attenuates the consolidation of remote fear memories of mice, without affecting their expression and retention. Rats treated with different doses of DMP696 (1, 3, 10, 30 mg/kg) show very little freezing during the 2-minute preshock interval. WT mice treated with DMP696 for 1 week starting 24?h after foot shock also display reduced synaptosomal GluR1 levels than do shocked vehicle-treated controls [1]. Rats treated with DMP696 show a significant overall reduction in CREB phosphorylation, in both the LA, and BLA, but not in the CeA. In the CeA, both vehicle- and DMP696-treated rats display obviously higher pCREB expression at each post-conditioning time interval than homecage pCREB levels. Rats in the 30 ng DMP696 group exhibit significantly less freezing in comparison to vehicle-treated animals [2].